Company: ABBV
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001104659-25-014554
Chunk: 14

Company: AbbVie Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 14
---
                    | ​ | ​ | ​                       | $ | 70,469 | ​ | ​ | ​ | ​           | ​ |     ​ | ​ | ​ |
| ​                                       |   |   |                         |   |        |   |   |   |             |   |       |   |   |

(a) Subsequent to December 31, 2024, AbbVie issued commercial paper borrowings of which $3.3 billion were outstanding as of February 14, 2025. Subsequent to December 31, 2024, in addition to the existing $5.0 billion 2028 Revolving Credit Facility, AbbVie entered into the new $3.0 billion 2030 Revolving Credit Facility, which matures in January 2030. There are currently no amounts outstanding under the Revolving Credit Facilities. (b) Includes $2.890 billion of senior unsecured notes issued by AbbVie and $130.225 million of senior unsecured notes issued by Allergan Funding SCS (formerly known as Actavis Funning SCS), a wholly owned subsidiary of AbbVie as of May 8, 2020. (c) Based on a U.S. dollar to Euro exchange rate as of December 31, 2024. (d) Excludes the impact of the Notes offered hereby.

S-11

TABLE OF CONTENTS

### DESCRIPTION OF NOTES
The Notes will be issued under an indenture, dated as of November 8, 2012 (the “ indenture ”), between AbbVie and U.S. Bank Trust Company, National Association, as successor to U.S. Bank National Association, as trustee (the “ Trustee ”), as supplemented by one or more supplemental indentures relating to the Notes. The following description of the terms of the Notes supplements, and, to the extent it is inconsistent therewith replaces, the description of the general terms of debt securities set forth in the accompanying prospectus, to which description reference is hereby made. The following summary of certain provisions of the indenture and the Notes does not purport to be complete and is subject to, and is qualified in its entirety by reference to, all the provisions of the indenture and the Notes, including the definitions of certain terms therein and those terms made part thereof by the Trust Indenture Act of 1939 (the “ Trust Indenture Act ”), as amended. In this description all references to “AbbVie,” “we,”